A Study of LASN01 in Patients with Thyroid Eye Disease (H-54339)

A Phase 2, Proof-of-Concept, Randomized, Double-Masked, Placebo-Controlled Study to determine the Efficacy and Safety of LASN01 in Patients with Thyroid Eye Disease

We are currently running a clinical study for patients with thyroid eye disease (TED).

The purpose of the research is to evaluate the safety and effectiveness of an investigational study drug called LASN01 on patients with TED. LASN01 is an antibody medication that is directed against a human protein called the IL-11 receptor. IL-11 receptor is believed to be the starting point of the complex cellular process that causes inflammation and bulging eyes that can eventually lead to TED. By blocking the IL-11 receptor, it is believed that LASN01 can prevent the progress of TED symptoms.

The study will enroll approximately 24 patients with TED who have not received prior anti-IGF-1R treatment.

Subject eligibility:

• Over 18 years old
• Have been diagnosed with TED
• Have been experiencing TED symptoms for less than 15 months